- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Danish Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
4
High return on equity, past performance and sound balance sheet.
4 companies
ChemoMetec
Market Cap: DKK 10.6b
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
CHEMM
DKK 609.50
7D
12.5%
1Y
34.3%
Genmab
Market Cap: DKK 110.8b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,800.00
7D
2.8%
1Y
0%
Gubra
Market Cap: DKK 6.2b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 379.20
7D
-4.0%
1Y
-25.4%
Zealand Pharma
Market Cap: DKK 29.0b
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
ZEAL
DKK 412.40
7D
-7.9%
1Y
-55.0%